Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01704781Phase 1Completed

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Role: lead

NCT01712256Phase 2Completed

Re-boosting of HIV-1 Infected Subjects With Vacc-4x

Role: lead

NCT02092116Phase 1Completed

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

Role: lead

NCT00659789Phase 2Completed

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

Role: lead

NCT01627678Phase 1Completed

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

Role: lead

NCT01473810Phase 1Completed

Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant

Role: collaborator

All 6 trials loaded